The company we keep: why physicians should refuse to see pharmaceutical representatives
- PMID: 15671196
- PMCID: PMC1466797
- DOI: 10.1370/afm.259
The company we keep: why physicians should refuse to see pharmaceutical representatives
Abstract
Whether physicians ought to interact with pharmaceutical sales representatives (reps) is a question worthy of careful ethical analysis. The issue presents a challenge to both professional integrity and time management. Empirical data suggest that interactions with pharmaceutical reps increase the chances that the physician will act contrary to duties owed to the patient. Ideally, a physician might both interact with reps and also do the research necessary to counteract the commercial bias in their messages. But a physician who actually did that research would, in turn, be devoting a good deal of time that might better be spent in other activities. The counterargument, that one is obligated to see representatives to obtain free samples to best serve one's patients, can be shown in most practice settings not to be compelling. Physicians ought to refuse to visit with representatives as a matter of both professional integrity and sensible time management.
Similar articles
-
Interactions between doctors and pharmaceutical sales representatives in a former communist country. The ethical issues.Camb Q Healthc Ethics. 2014 Jul;23(3):349-55. doi: 10.1017/S0963180113000960. Epub 2014 May 27. Camb Q Healthc Ethics. 2014. PMID: 24865182
-
[Dangerous liaisons--physicians and pharmaceutical sales representatives].Acta Med Port. 2005 Jan-Feb;18(1):61-8. Epub 2005 Mar 11. Acta Med Port. 2005. PMID: 16202335 Review. Portuguese.
-
Factors associated with physicians' reliance on pharmaceutical sales representatives.Acad Med. 2009 Aug;84(8):994-1002. doi: 10.1097/ACM.0b013e3181ace53a. Acad Med. 2009. PMID: 19638762
-
The pharmaceutical sales rep/physician relationship in Turkey: ethical issues in an international context.Health Mark Q. 2004;22(1):21-39. doi: 10.1300/j026v22n01_03. Health Mark Q. 2004. PMID: 15914382
-
Pharmaceutical sales representatives and the doctor/patient relationship.Obstet Gynecol. 2002 Sep;100(3):594-9. doi: 10.1016/s0029-7844(02)02150-6. Obstet Gynecol. 2002. PMID: 12220784 Review.
Cited by
-
Big Pharma: a former insider's view.Med Health Care Philos. 2013 May;16(2):249-64. doi: 10.1007/s11019-012-9388-6. Med Health Care Philos. 2013. PMID: 22351152
-
Educating health professionals about drug and device promotion: advocates' recommendations.PLoS Med. 2006 Nov;3(11):e451. doi: 10.1371/journal.pmed.0030451. PLoS Med. 2006. PMID: 17090212 Free PMC article.
-
The high costs of "free" drug samples.Clin Transl Gastroenterol. 2014 Dec 18;5(12):e67. doi: 10.1038/ctg.2014.16. Clin Transl Gastroenterol. 2014. PMID: 25521040 Free PMC article. No abstract available.
-
Use of atypical antipsychotics in nursing homes and pharmaceutical marketing.J Am Geriatr Soc. 2015 Feb;63(2):297-301. doi: 10.1111/jgs.13180. J Am Geriatr Soc. 2015. PMID: 25688605 Free PMC article. Clinical Trial.
-
The characteristics of conflict of interest in the doctor's pharmaceutical representative Relationship.Tunis Med. 2022 fevrier;100(2):127-132. Tunis Med. 2022. PMID: 35852246 Free PMC article.
References
-
- Sebra J. Drug reps and doctors took an undeserved hit. Wall Street Journal. July 12, 2002: A9.
-
- Rothman DJ. Medical professionalism—focusing on the real issues. N Engl J Med. 2000;342:1283–1286. - PubMed
-
- Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest. 1992;102:270–273. - PubMed
-
- Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283:373–380. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources